Seraphina Therapeutics has exclusive and global licensing rights from the U.S. Navy and the United States of America for general commercialization and use of C15:0 as a supplement, food or beverage ingredient, and pharmaceutical (U.S. Patent No. 11,116,740). In addition, our founders’ extensive science has enabled the fatty15 team to have exclusive patent rights across numerous specific indications, including (but not limited to) use of C15:0 to support:

• Metabolic health, including but not limited to addressing conditions relevant to glucose control, type 2 diabetes, and metabolic syndrome
• Heart health, including but not limited to addressing conditions relevant to dyslipidemia, vascular disease, and inflammation
• Liver health, including but not limited to addressing conditions relevant to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
• Immune health, including but not limited to lowering conditions relevant to inflammation
• Red blood cell health, including but not limited to addressing conditions relevant to anemia and iron dysmetabolic syndrome
• Healthy aging, including but not limited to addressing conditions relevant to age-related conditions and longevity
• Brain health
• Improved sleep
• Controlled appetite
• Improved mood, including but not limited to addressing conditions relevant to anxiety, depression, and drug addiction
• and more…

Beyond the general use of C15:0 and the many science-backed indications, our founders’ diligent science has also enabled Seraphina to have exclusive rights from the U.S. Navy and the United States of America around C15:0 formulations, oral dosing, and targeted C15:0 body levels. A list of many of the exclusively licensed patents to Seraphina Therapeutics and fatty15, including U.S. and international patents, is available below.

In summary, any entity other than fatty15 that is marketing or selling C15:0 as a supplement in the U.S. or any other covered countries, is infringing on patents from the U.S. Navy and the United States of America.